Relief of Symptomatic Vulvovaginal Atrophy

Guideline Watch |
October 3, 2013

Relief of Symptomatic Vulvovaginal Atrophy

  1. Anne Moore, DNP, APN, FAANP

NAMS has developed a comprehensive approach to management.

  1. Anne Moore, DNP, APN, FAANP

The North American Menopause Society (NAMS) has released an updated position statement that addresses a common consequence of estrogen loss in menopausal women: vulvovaginal atrophy (VVA). Almost half of postmenopausal women have reported experiencing vaginal symptoms including dryness, irritation, and pain with intercourse, but very few understand the relation of these symptoms to menopause or discuss them with a healthcare provider. The NAMS statement includes information about the evaluation, diagnosis, and treatment of VVA.

Highlights of the recommendations are as follows:

  • First-line treatments for symptomatic VVA include lubricants and long-acting vaginal moisturizers.

  • For persistent or moderate-to-severe VVA, low-dose vaginal or systemic estrogen therapy represents standard treatment.

  • The recently approved oral selective estrogen-receptor modulator ospemifene may be used for dyspareunia.

  • Progestins are generally not indicated in the setting of low-dose vaginal estrogen (however, safety data beyond 1 year are lacking)

  • Whether or not vaginal estrogen is being used, vaginal spotting or bleeding in a postmenopausal woman with an intact uterus requires further evaluation.


Given that many women now live one third of their lives after menopause, their quality of life must be better recognized and addressed. This position statement provides a comprehensive approach to evaluation and management of vulvovaginal atrophy, a common and vexing problem. Although vaginal estrogen is most commonly prescribed for sexual discomfort caused by VVA, this class of medications also reduces urinary urgency and recurrent urinary tract infections associated with the condition. Accordingly, all women should be queried about vaginal symptoms and educated about VVA.

Editor Disclosures at Time of Publication

  • Disclosures for Anne Moore, DNP, APN, FAANP at time of publication Consultant / Advisory board Watson


Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.